Table 2.
Multivariate logistic regression analysis by pathological complete response (pCR) status
| Variable | OR (95% CI) | P value |
|---|---|---|
| Clinical stage | ||
| Stage III | (reference) | |
| Stage II | 1.94 (1.53–2.45) | <0.001 |
| ER, continuous | 0.990 (0.986–0.994) | <0.001 |
| PR, continuous | 0.989 (0.984–0.995) | <0.001 |
| Race/ethnicity | ||
| White | (reference) | |
| Black | 1.18 (0.88–1.58) | 0.28 |
| Hispanic | 1.37 (1.00–1.85) | 0.04 |
| Asian/Others | 0.87 (0.52–1.45) | 0.58 |
| Histology | ||
| Ductal | (reference) | |
| Lobular | 0.36 (0.14–0.90) | 0.03 |
| Others | 0.510 (0.226–1.000) | 0.05 |
| Nuclear grade | ||
| III | (reference) | |
| I/II | 0.45 (0.32–0.63) | <0.001 |
| Neoadjuvant regimen | ||
| A+T | (reference) | |
| A | 0.30 (0.17–0.52) | <0.001 |
| T | 0.26 (0.10–0.66) | 0.004 |
OR, odds ratio; CI, confidential interval; ER, estrogen receptor; PR, progesterone receptor; A + T, anthracycline and taxane; A, anthracycline; T, taxane.